The use of nomograms in the detection of prostate cancer

Prostate

Volumn 66, Issue 12, 2006, Pages 1266-1267

  Roobol, M J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; SHORT SURVEY; ALGORITHM; ARTICLE; BIOPSY; BLOOD; DIGITAL RECTAL EXAMINATION; MALE; NOMOGRAM; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; PROSTATE TUMOR; REGRESSION ANALYSIS;

PROSTATE SPECIFIC ANTIGEN;

ALGORITHMS; BIOPSY; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS;

EID: 33748359356     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20454     Document Type: Short Survey

References (10)

1. Sackett DL, et al. Evidence-based medicine: How to practice and teach EBM. New York: Churchill Livingstone, 2000.
2. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58(6):843-848.
3. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, Shariat SF, Slawin KM, Ohori M. Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170(5):1792-1797.
4. Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL. Cancer 2003;98(7):1417-1422.
5. Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 2002;20(4):921-929.
6. Roobol MJ, Schröder FH. (guest editors). European Randomized Study of Screening for Prostate Cancer: Achievements and presentation 1993-2003. BJU Int 2003;92(Suppl 2):1-122.
7. Roobol MJ, Schroder FH, Kranse R. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). Prostate 2006;66(6):604-612.
8. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21(6 Suppl):273S-309S.
9. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK, PLCO Project Team. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005;97(6):433-438.
10. Pinsky PF, Andriole GL, Kramer BS, Hayes RB, Prorok PC, Gohagan JK, Prostate, Lung, Colorectal and Ovarian Project Team. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol 2005;173(3):746-750; discussion 750-751.